Legal Updates

Corporate Law – Mergers & Acquisitions - Competition Law - Conditional Clearance - Healthcare – Divestment of Business

The European Commission (EC) has granted conditional clearance to the share acquisition of Pfizer Inc.'s entire consumer healthcare division (PCH) by Johnson & Johnson (J&J) under Article 6(2) of the EC Merger Regulation. The acquisition gave control over PCH.  This constituted a concentration within the meaning of Article 3(1)(b) of the Merger Regulation.  As part of the conditions attached to this acquisition, Johnson & Johnson agreed to divest its activities in three product markets:-

  • over-the-counter topical dermatological anti-fungal formulations
  • nicotine patches; and
  • daily-use mouthwash

J&J is a group active worldwide in three business segments:
 

  • consumer products;
  • pharmaceuticals; and
  • medical devices and diagnostics.


PCH is Pfizer’s worldwide business division active in personal care products and over-the-counter pharmaceutical products (“OTC products”). OTC products represent 70% to 80% of PCH’s revenues.  The EC believed that this divestiture took into account the interests of other viable businesses and addressed competition issues.
   

SearchBox

Search Shadow

NewsLetterBox

newsletter Shadow

TestimonialBox

Testimonial Bottom Shadow

testimonial Shadow Middle

More Testimonials

Testimonial Bottom Shadow